In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of metabolic diseases, offering substantial benefits in glycemic control, weight reduction, cardiovascular ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation ... receiving any of these LA GLP1-RAs. However, there are several ongoing trials ...

For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

GLP-1RAs were associated with improved quality of life and emotional eating behaviors among individuals with overweight and obesity.

New research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...